influenza-2016_keynote

4 / 9

Volume 4, Issue 6(Suppl) J Infect Dis Ther
ISSN: 2332-0877 JIDT, an open access journal Influenza 2016
September 12-13, 2016
Page 22
Notes:
conferenceseries.com
Influenza
September 12-13, 2016 Berlin, Germany
2nd International Conference on
Palayakotai Raghavan, J Infect Dis Ther 2016, 4:6(Suppl)
Controlling viral infection with Metadichol
Metadichol (US patent 8,722,093) is a nano-emulsion of long-chain alcohols found in many foods. It is commonly called
Policosanol and is present in foods such as rice, sugar cane, wheat, peanuts. Metadichol acts on Nuclear Vitamin D
receptors (VDR) (US patent 9,006,292) that are present in cells throughout the body to stimulate the immune system and
inhibit a variety of disease processes, resulting from viral infections. We tested for antiviral activity of Metadichol® in Vero and
MDCK cells infected with Influenza A, H1N1, Human Respiratory Syncytial virus, Dengue, Chikungunya and Ebola, Marburg.
In addition, we tested the efficacy of Metadichol® in preventing cell death caused by Adenovirus, Tacaribe Mammarena virus,
Rift Valley Fever virus, SARS coronavirus, Japanese Encephalitis virus, West Nile virus, and Yellow Fever virus. In the in vitro
assays, Metadichol showed no cytotoxicity and strongly inhibited cell death caused by each of the viruses tested. Metadichol
is a safe and effective inhibitor of enveloped viruses in humans. Since it is known to bind to the vitamin D receptor (VDR)
(US patent 9,006,292), its mechanism of action likely involves the competitive displacement of virus particles from VDR’s on
host cell membranes. Because it consists of natural components of common foods and has no known negative side effects,
Metadichol has the potential to serve as a novel, broad-spectrum antiviral treatment for Dengue, Ebola, Zika, H1N1, SARS,
Chikungunya and other enveloped viruses.
Biography
Palayakotai Raghavan is the CEO and Founder of Nanorx Inc., New York, USA. He has completed his PhD in Organic Chemistry from Oregon State University
in 1979 and MS in Chemistry in 1972 from IIT Mumbai, India. He has worked on drug discovery for over 25 years at Columbia University, Max-Planck Institute,
Germany, Ciba-Geigy (now Novartis) and Boehringer Ingelheim. He has over 12 patents and another 15 pending patent applications.
Palayakotai Raghavan
Nanorx Inc., USA